Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells

Epidermal growth factor receptor - tyrosine kinase inhibitor (EGFR-TKI) is the first choice of treatment for advanced non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, single agent usually has limited efficacy due to heterogeneous resistant mechanisms of canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Miao, Yuang-Chi Chang, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893260/
https://www.ncbi.nlm.nih.gov/pubmed/29662665
http://dx.doi.org/10.18632/oncotarget.24814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893260/
https://www.ncbi.nlm.nih.gov/pubmed/29662665
http://dx.doi.org/10.18632/oncotarget.24814

Ejemplares similares